Microarray pathway analysis indicated that mitogen-activated protein kinase/extracellular signal-regulated kinase and insulin growth factor 1 signaling pathways were inhibited by small interfering RNA against AT‑rich interactive domain 1A in endometrial cancer

Yang,Ye; Bao,Wei; Sang,Zhengyu; Yang,Yongbing; Lu,Meng; Xi,Xiaowei

doi:10.3892/ol.2017.7489

Microarray pathway analysis indicated that mitogen-activated protein kinase/extracellular signal-regulated kinase and insulin growth factor 1 signaling pathways were inhibited by small interfering RNA against AT‑rich interactive domain 1A in endometrial cancer

Authors:
- Ye Yang
- Wei Bao
- Zhengyu Sang
- Yongbing Yang
- Meng Lu
- Xiaowei Xi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, P.R. China, Department of Obstetrics and Gynecology, Shanghai General Hospital of Shanghai Jiaotong University, Shanghai 200080, P.R. China
Published online on: November 24, 2017 https://doi.org/10.3892/ol.2017.7489
Pages: 1829-1838

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mutations in the gene encoding AT-rich interactive domain 1A (ARID1A) are frequently observed in endometrial cancer (EC) but the molecular mechanisms linking the genetic changes remain to be fully understood. The present study aimed to elucidate the influence of ARID1A mutations on signaling pathways. Missense, synonymous and nonsense heterozygous ARID1A mutations in the EC HEC‑1‑A cell line were verified by Sanger sequencing. Mutated ARID1A small interfering RNA was transfected into HEC‑1‑A cells. Biochemical microarray analysis revealed 13 upregulated pathways, 17 downregulated pathways, 14 significantly affected disease states and functions, 662 upstream and 512 downstream genes in mutated ARID1A‑depleted HEC‑1‑A cells, among which the mitogen‑activated protein kinase/extracellular signal‑regulated kinase and insulin‑like growth factor‑1 (IGF1) signaling pathways were the 2 most downregulated pathways. Furthermore, the forkhead box protein O1 pathway was upregulated, while the IGF1 receptor, insulin receptor substrate 1 and phosphatidylinositol-4,5-bisphosphate 3‑kinase catalytic subunit b pathways were downregulated. Carcinoma tumorigenesis, tumor cell mitosis and tumor cell death were significantly upregulated disease states and functions, while cell proliferation and tumor growth were significantly downregulated. The results of the present study suggested that ARID1A may be a potential prognostic and therapeutic molecular drug target for the prevention of EC progression.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Wang Y, Zhu Y, Zhang L, Tian W, Hua S, Zhao J, Zhang H and Xue F: Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett. 322:223–231. 2012. View Article : Google Scholar : PubMed/NCBI
3	de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, et al: Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open label, multicentre, randomised, phase 3 trial. Lancet Oncol. 17:1114–1126. 2016. View Article : Google Scholar : PubMed/NCBI
4	Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res. 22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
5	Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wu CH, Wang TL and Shih IeM: Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol. 37:1342–1348. 2013. View Article : Google Scholar : PubMed/NCBI
6	Er TK, Su YF, Wu CC, Chen CC, Wang J, Hsieh TH, Herreros-Villanueva M, Chen WT, Chen YT, Liu TC, et al: Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer. J Mol Med (Berl). 94:835–847. 2016. View Article : Google Scholar : PubMed/NCBI
7	Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et al: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 330:228–231. 2010. View Article : Google Scholar : PubMed/NCBI
9	Zhai Y, Kuick R, Tipton C, Wu R, Sessine M, Wang Z, Baker SJ, Fearon ER and Cho KR: Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival. J Pathol. 238:21–30. 2016. View Article : Google Scholar : PubMed/NCBI
10	Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ and Shih IeM: Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 22:1310–1315. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wu JN and Roberts CW: ARID1A mutations in cancer: Another epigenetic tumor suppressor? Cancer Discov. 3:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
12	Arocho A, Chen B, Ladanyi M and Pan Q: Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn Mol Pathol. 15:56–61. 2006. View Article : Google Scholar : PubMed/NCBI
13	Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al: Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 44:570–574. 2012. View Article : Google Scholar : PubMed/NCBI
14	Gagnon V, Mathieu I, Sexton E, Leblanc K and Asselin E: AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol. 94:785–795. 2004. View Article : Google Scholar : PubMed/NCBI
15	Trabert B, Wentzensen N, Felix AS, Yang HP, Sherman ME and Brinton LA: Metabolic syndrome and risk of endometrial cancer in the United States: A study in the SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev. 24:261–267. 2015. View Article : Google Scholar : PubMed/NCBI
16	Stocks T, Bjørge T, Ulmer H, Manjer J, Häggström C, Nagel G, Engeland A, Johansen D, Hallmans G, Selmer R, et al: Metabolic risk score and cancer risk: Pooled analysis of seven cohorts. Int J Epidemiol. 44:1353–1363. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Hua S, Tian W, Zhang L, Zhao J, Zhang H, Zhang W and Xue F: Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent. Gynecol Oncol. 125:734–741. 2012. View Article : Google Scholar : PubMed/NCBI
18	McCampbell AS, Walker CL, Broaddus RR, Cook JD and Davies PJ: Developmental reprogramming of IGF signaling and susceptibility to endometrial hyperplasia in the rat. Lab Invest. 88:615–626. 2008. View Article : Google Scholar : PubMed/NCBI
19	Le Roith D: The insulin-like growth factor system. Exp Diabesity Res. 4:205–212. 2003. View Article : Google Scholar : PubMed/NCBI
20	Bruchim I, Sarfstein R, Reiss A, Flescher E and Werner H: IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer. Cancer Lett. 352:214–219. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Gao C, Zhang Y, Gao J, Teng F, Tian W, Yang W, Yan Y and Xue F: Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways. Gynecol Oncol. 143:168–178. 2016. View Article : Google Scholar : PubMed/NCBI
22	Ogawa K, Sun C and Horii A: Exploration of genetic alterations in human endometrial cancer and melanoma: Distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade. Oncol Rep. 14:1481–1485. 2005.PubMed/NCBI
23	Li Y, Jia Y, Che Q, Zhou Q, Wang K and Wan XP: AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma. Oncotarget. 6:26373–26387. 2015. View Article : Google Scholar : PubMed/NCBI
24	Tao Y, Pinzi V, Bourhis J and Deutsch E: Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol. 4:591–602. 2007. View Article : Google Scholar : PubMed/NCBI
25	Ewing GP and Goff LW: The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer. 9:219–223. 2010. View Article : Google Scholar : PubMed/NCBI
26	Tognon CE and Sorensen PH: Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets. 16:33–48. 2012. View Article : Google Scholar : PubMed/NCBI
27	Campbell M, Allen WE, Sawyer C, Vanhasebroeck B and Trimble ER: Glucose-potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk between the PI3K and MAPK signaling pathways. Circ Res. 95:380–388. 2004. View Article : Google Scholar : PubMed/NCBI
28	Ward EC, Hoekstra AV, Blok LJ, Hanifi-Moghaddam P, Lurain JR, Singh DK, Buttin BM, Schink JC and Kim JJ: The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma. Endocrinology. 149:1942–1950. 2008. View Article : Google Scholar : PubMed/NCBI